---
layout: post
title: "Nonclinical Evaluation of the Immunotoxic Potential of Pharmaceuticals; Guidance for Industry; Availability"
date: 2026-02-05 18:55:45 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2023-11898
original_published: 2023-06-05 00:00:00 +0000
significance: 8.00
---

# Nonclinical Evaluation of the Immunotoxic Potential of Pharmaceuticals; Guidance for Industry; Availability

**Published:** February 05, 2026 18:55 UTC
**Source:** Federal Register
**Original Published:** June 05, 2023 00:00 UTC
**Document Number:** 2023-11898

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled "Nonclinical Evaluation of the Immunotoxic Potential of Pharmaceuticals." This guidance finalizes the draft guidance entitled "Nonclinical Safety Evaluation of the Immunotoxic Potential of Drugs and Biologics" issued on February 20, 2020.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2023/06/05/2023-11898/nonclinical-evaluation-of-the-immunotoxic-potential-of-pharmaceuticals-guidance-for-industry)
- API: https://www.federalregister.gov/api/v1/documents/2023-11898

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
